|Herbal Medical Center | 麻省中医医院 |Hi-Tech Herbal Remeday| RedSun Institute | Boston-rent|
Since 1996 we have constantly studied roles of Cancer Preventer-1# in preventing development of multiple types of primary malignant tumors in mice.
We have confirmed that Cancer Preventer-1# is a highly effective herbal product in the prevention of development of murine malignant tumors in C57BL6 mice. To verify our in vivo results are trustable we tested the role of Cancer Preventer-1# ex vivo anti-tumor in a separated university laboratory in the USA. The data showed that Cancer Preventer-1# at the concentration of 60mg/ml inhibited proliferation of human prostate and breast cancer cells in tissue culture.
In vivo experimental models showed that after orally taking Cancer Preventer-1#at the dose of 100mg/kg body weight/day for constitutive 30 days the experimental C57BL6 mice were challenged subcutaneously with 2x106 cells of mouse MCA207 sarcoma, MC38 colorectal cancer and B16F1 melanoma in each mouse. A 3-month follow-up study demonstrated that no tumor growth was founded in mice which had orally taken Cancer Preventer-1#, but tumors grew in control animals.
Our studies proved that Cancer Preventer-1# could effectively prevent the establishment of primary tumors of MCA207 mouse sarcoma and MC38 mouse colorectal adenocarcinoma and slowed down the growth of established murine melanoma, indicating that Cancer Preventer-1# has not only the role in preventing the occur of primary tumors but also it has highly therapeutic effect on the established mouse tumors.
LDL-110 is the abbreviation of Mr. Liu De Li’s name, who is Dr. David Liu’s grand father. This new anti-cancer drug was discovered in the year of Mr. Liu De Li’s 110th birthday.
We have identified a new and effective broad-spectrum anti-cancer drug, LDL-110, from a subtropical plant. Tumor-killing mechanisms of LDL-110 consist of induction of apoptosis, inhibition of DNA synthesis and change in cell cycle of tumor cells.
Ex vivo studies showed that LDL-110 significantly killed human lung cancer (A549, H1299), breast cancer (T470, MB23, McF-7) and prostate cancer (LNcap, PC3, DU145, CWR-22), liver cancer (Hu-77), colorectal cancer (MIP-101), melanoma (M24), lymphoma (DL1, DL2, DL3) and leukemia (K562) cells. When LDL-110 was administered at the dose of 60 mmol in tissue culture for 48 hours, 75% to 85% of tumor cells underwent apoptosis or death. When these tumor cells were consecutively treated in tissue culture for 120hs 96% to 100% of tumor cells were killed. Compared to classic anti-cancer drug mitomycin, LDL-110 is 6-times more effective than mitomycin in tissue culture.
A preliminary in vivo study showed 12 types of human tumor cells were implanted in nude mice and LDL-110 at the dose of 0.47mg/kg/day was I.P. administered, tumor growth significantly inhibited in all of 12 types of tumors. We established a new tumor model that 6 types of human cancer cell lines were implanted in a nude mouse and the animals then were treated with LDL-110 to observe which types of cancer cell lines were sensitive to the drug. Five of 6 types of human cancer regressed (see the pictures in presentation-1 in this website).
More importantly, LDL-110 can be taken by mouth and it shows a low cytotoxicity at the effective therapeutic dose ex vivo and in vivo. As converted to the oral dose of LDL-110, it is taken by mouth at the dose of 300 to 600mg, 3 to 4 times a day in an adult of 50 kg body weight.
We have developed three types of personalized hybrid tumor vaccines. Allogeneic hybrid tumor vaccines, using gene transfected DLL46 antigen presenting cells (APCs) as amplifiers of tumor antigens, have made breakthrough progress in treatment of mouse tumors, and also potentially in human cancers.
As shown in the presentation of tumor vaccines, con-focal microscopic pictures 1-4, the red color represents a LNcap human prostate cancer cell and the green color represents a DLL46 antigen presenting cell, and the golden color represents a mixed both colors of red and green, means a successful hybridization.
Fusion of gene transfected DLL46 APCs with MCA207 mouse sarcoma cells generated efficient D-MCA hybrid tumor vaccines that cured all of sarcoma-bearing C56BL6 mice after a single immunization. Fusion of gene transfected DLL46 APCs with B16F1 mouse melanoma cells developed efficient D-B16F1 hybrid tumor vaccines that cured all of small melanoma (the tumor size was < 5mm in diameters) and inhibited the growth of large melanoma (the tumor size was > 6mm in diameters) after double immunizations.
We have designed a technical system for producing hybrid tumor vaccines that has reached a semi-industrialized capacity.
LIP is the abbreviation of a new type of tumor vaccines that is composed of 3 types of bio-immunological substances. LIP tumor vaccines are capable of eliciting both specific and non-specific anti-tumor immunity against tumor antigens. LIP tumor vaccine is directly administrated into solid tumors. Microscopically, large number of activated T cells, mononuclear phagocytes and leukocytes recruited to the tumors and in the surrounding tissue of the tumors after a single immunization. Many small tumors at the size <5mm in diameters were cured by a single dose of LIP tumor vaccines in C57BL6 mice and nude mice.
Our creative studies have demonstrated that failed recognition of tumor-specific antigens by the immune system of the body is an issue of insufficient expression of tumor-specific antigens to the immune system. We have observed regardless a young recipient or an elderly one who receives an allograft is able to reject a transplanted liver, lung or kidney. This fact strongly suggests that an individual should have sufficient immunity to reject a tumor weighing 1,000 to 2,000 grams if a specific immune reaction against tumor-specific antigens can be evoked.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic hematopoietic growth factor that induces both growth and differentiation of monocytes and macrophages. Recombinant human GM-CSF (rhGM-CSF) with recombinant human interleukin 4 (rhLI-4) have been used in developing RedSun’s dendritic cell programs.
These cytokines, however, have their disadvantage, for example, the half-life of natural GM-CSF in vivo is only about 15 minutes, ranged from 13 to 40 minutes. Apparently, this is inconvenient to apply in clinic practice. To overcome the disadvantage of short-circulating half-life of natural human GM-CSF, scientists at RedSun have used the newest technology in development of fusion protein therapy. The rhGM-CSF and rhIL-4 gene transfected mammalian cells make 4mg /ml /106 cells /day in our laboratory.
The data of comparative studies from our laboratory have shown that mean half-life of natural GM-CSF and IL4 in nude mice is approximately 15 minutes. However, our long acting rhGM-CSF is still detectable by 3 weeks after a single i.p. injection in nude mice. This study confirmed that the clearance time of RedSun’s long-acting hGM-CSF is 300 folds longer than natural one.
As shown in the pictures of dendritic cells in the presentation of Hybrid Tumor Vaccines, human peripheral blood-derived dendritic cells were successfully developed and proliferated in tissue culture with our long-acting rhGM-CSF and long-acting rhIL-4, indicating both types of long-acting recombinant human cytokines are highly biological activity.